Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Updated Framework Guides Assessment of Actionable Cancer Biomarkers

By LabMedica International staff writers
Posted on 27 Oct 2026

Cancer care increasingly relies on molecular testing to guide targeted treatment selection. More...

Broader use of tumor sequencing has expanded the volume and diversity of biomarker data available to oncologists, while also making interpretation more complex. In particular, clinicians must distinguish alterations that predict treatment benefit from those associated with resistance. In response to this growing complexity, researchers have developed an updated framework for ranking molecular alterations in precision oncology.

The European Society for Medical Oncology (ESMO) has published version 2 of the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT v2). The framework is designed to help oncologists assess the clinical relevance of molecular alterations and match patients with appropriate targeted therapies. First introduced in 2018, ESCAT provided a common language for ranking genomic alterations according to the strength of evidence supporting their use in precision oncology.

ESCAT v2 retains the original scale’s core principles while adding refinements intended to improve clarity and consistency. The updated framework restructures Tier I to distinguish between different levels of certainty supporting a biomarker-treatment match while maintaining the same clinical recommendation for use. It also incorporates formal criteria for evaluating tumor-agnostic therapies through alignment with ESMO’s Tumor-Agnostic Classifier and Screener.

The framework provides more granular guidance on the use of prospective and real-world evidence and refines lower tiers to reflect current evidence-generation pathways. ESCAT v2 also introduces a parallel resistance scale for classifying biomarkers associated with reduced or absent treatment benefit. The new scale was developed independently of regulatory approvals and is intended to support therapeutic sequencing and treatment selection.

ESCAT v2 was published in Annals of Oncology on October 21, 2026. The updated framework is intended for integration into molecular diagnostic reports, molecular tumor board discussions, clinical practice guidelines, and routine treatment planning. ESMO states that the framework supports more consistent application of precision medicine across health care systems.

“Precision oncology has matured considerably since the original ESCAT was published. Clinicians today are faced with a far greater volume and diversity of biomarker information than ever before. ESCAT v2 provides a more nuanced and practical framework for interpreting both actionability and resistance biomarkers, helping translate increasingly complex molecular data into treatment decisions that benefit patients,” said Dr. Aya El Helali, first author of the Annals of Oncology paper.

Related Links
European Society for Medical Oncology


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Automatic CLIA Analyzer
Shine i6000
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers combined a blood-based biomarker of Alzheimer’s disease with age, sex, and genetic risk to estimate future cognitive impairment risk in asymptomatic adults (Image Credit: Adobe Stock)

Blood Biomarker Model May Help Estimate Five- and 10-Year Cognitive Impairment Risk

Estimating future cognitive impairment risk remains challenging in cognitively healthy adults, particularly when biomarker findings are reduced to simple positive or negative results. Because mild cognitive... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Malaria is caused by Plasmodium parasites, primarily transmitted through the bites of infected female Anopheles mosquitoes (Image Credit: Adobe Stock)

Complete Malaria Genomes Could Improve Species Identification and Surveillance

Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.